About Tempus AI, Inc. - Class A Common Stock (TEM)
Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting the impact of AI and real-world data on health economics and outcomes research.
PALM BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated the capability to analyze vast amounts of medical data, including patient records and genetic information. This efficiency allows healthcare professionals to diagnose conditions more quickly and accurately, leading to better patient outcomes. AI-powered diagnostic tools can detect subtle patterns and indicators of diseases; this offers early detection and further works on early prevention of diseases. AI systems also help in assisting healthcare professionals with valuable tools, all these factors that offer improved diagnosis process act as a driver for the market’s growth. A report from MarketsAndMarkets projected that the global AI in medical diagnostics market is forecasted to grow at a robust CAGR of 22.5%, reaching US$1.71 billion in 2024 and an impressive US$4.72 billion by 2029. The report said: “Government initiatives towards increasing Al-based technologies, access to finance for Al-based startups, big data influx, and growing cross-industry alliances and collaborations are key drivers of this market's growth. Growth in the AI in medical diagnostics market is primarily driven by the growing demand for AI tools, increasing focus on reducing the workload of radiologists, influx of large & complex datasets, funding for AI based startups, and growing cross-industry partnerships & collaborations.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), Teladoc Health, Inc. (NYSE: TDOC), GE HealthCare (NASDAQ: GEHC).
CoreWeave is arguably the most talked-about new stock in 2025. What is to make of this AI cloud infrastructure firm with a significant investment from NVIDIA?
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology."
Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision medicine and patient care company reports a first-quarter adjusted loss of 24 cents per share, beating analyst estimates for a loss of 27 cents per share, according to Benzinga Pro.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients’ electronic health records.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants including resistance mutations, identify clinically relevant biomarkers, and monitor disease progression.
PALM BEACH, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to reports from industry insiders the Global AI in Diabetic Retinopathy market is projected to continue to grow at a substantial rate for years to come. According to Metastat, Global AI in Diabetic Retinopathy Market is witnessing unprecedented growth, reshaping the landscape of diagnostic and therapeutic interventions for this prevalent and sight-threatening complication of diabetes. As technology continues to advance, artificial intelligence (AI) is emerging as a transformative force in healthcare, particularly in the domain of diabetic retinopathy (DR), where early detection and timely intervention are critical. The report said “AI applications in diabetic retinopathy are gaining momentum due to their ability to augment traditional diagnostic methods. Image analysis, a cornerstone in the detection of retinal abnormalities, has witnessed a paradigm shift with the incorporation of AI algorithms. These algorithms, trained on vast datasets of retinal images, demonstrate remarkable accuracy in identifying subtle changes indicative of diabetic retinopathy. Consequently, they empower healthcare professionals with more efficient and precise tools for early diagnosis. One of the notable contributions of AI in diabetic retinopathy lies in its potential to address the challenge of limited access to ophthalmic expertise, especially in resource-constrained regions. Automated screening processes, driven by AI, enable remote and quick assessment of retinal images, offering a scalable solution to bridge the gap in healthcare accessibility. This democratization of expertise has the potential to revolutionize the way diabetic retinopathy is diagnosed and managed globally.” According to a report issued by Grand View Research: “the global diabetic retinopathy market size was estimated at USD $9.48 Billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Recursion (NASDAQ: RXRX), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), ADMA Biologics, Inc. (NASDAQ: ADMA).
